Ipilimumab-induced encephalopathy with a reversible splenial lesion

Cancer Immunology Research

Volumn 3, Issue 6, 2015, Pages 598-601

  Conry, Robert M ^a   Sullivan, Joseph C ^b   Nabors III, Louis B ^c  

^a Heerskink School of Medicine   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; GADOLINIUM; IPILIMUMAB; METHYLPREDNISOLONE; PREDNISONE; PROTEIN; STEROID; TAMSULOSIN; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; ATAXIC APHASIA; ATAXIC GAIT; BONE METASTASIS; BRAIN DISEASE; CASE REPORT; CHILL; COMPUTER ASSISTED TOMOGRAPHY; CORPUS CALLOSUM; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSMETRIA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; LEUKOCYTE; LIVER METASTASIS; LYMPH NODE METASTASIS; MACULOPAPULAR RASH; MALE; MEMORY DISORDER; METASTATIC MELANOMA; MONOTHERAPY; MOTOR DYSFUNCTION; MYALGIA; NEUROGENIC BLADDER; NEUROIMAGING; NEUROLOGIC EXAMINATION; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PLEOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; POSTVOID RESIDUAL URINE VOLUME; PROPRIOCEPTION; SEROLOGY; SPEECH DISORDER; STEROID THERAPY; TOPICAL TREATMENT; TREATMENT WITHDRAWAL; TREMOR; URINE RETENTION; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN DISEASES; COMPLICATION; DRUG EFFECTS; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; SPLEEN;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN DISEASES; CTLA-4 ANTIGEN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; SPLEEN;

EID: 84961875164     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0035     Document Type: Article

References (16)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Lebbe C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014;25:2277-84.
3. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
4. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
5. Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012;30:e76-8.
6. Weber JS, Kahler KC, Hauschild A. Management ofimmune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.
7. Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009;32:203-5.
8. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-oncology 2014;16:589-93.
9. Okamoto T, Sato Y, Yamazaki T, Hayashi A. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion associated with febrile urinary tract infection. Eur J Pediatrics 2014;173:533-6.
10. Tada H, Takanashi J, Barkovich AJ, Oba H, Maeda M, Tsukahara H, et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 2004;63:1854-8.
11. Maeda M, Tsukahara H, Terada H, Nakaji S, Nakamura H, Oba H, et al. Reversible splenial lesion with restricted diffusion in a wide spectrum of diseases and conditions. J Neuroradiology 2006;33:229-36.
12. Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012;35:169-78.
13. Kometani H, Kawatani M, Ohta G, Okazaki S, Ogura K, Yasutomi M, et al. Marked elevation of interleukin-6 in mild encephalopathywith a reversible splenial lesion (MERS) associated with acute focal bacterial nephritis caused by Enterococcus faecalis. Brain Dev 2014;36:551-3.
14. Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev 2009;31:521-8.
15. Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, et al. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res 2013;32:82.
16. Le EM, Loghin ME. Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients. Curr Oncol Reports 2014;16:383.